Table 3 Multivariable Cox regression analyses for the relative risks of developing various IMIDs in AS patients when compared with non-AS individuals
IMID | IMID occurred after the index date | Excluding those with IMID within 3 months after the index date | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Acute anterior uveitis | 9.07 (7.52–10.94)e | < 0.01 | 10.98 (9.10–13.25)e | < 0.01 |
Psoriasis | 1.69 (1.24–2.29)f | < 0.01 | 1.41 (1.01–1.96)e | 0.04 |
Inflammatory bowel disease | 2.11 (0.39–11.48)d | 0.39 | 0.35 (0.06–2.06)e | 0.24 |
Crohn’s disease | 8.01 (1.79–35.79)c | 0.01 | 2.74 (0.31–24.52)b | 0.37 |
Ulcerative colitis | 0.33 (0.05–2.37)f | 0.27 | 0.33 (0.05–2.37)f | 0.27 |
Systemic lupus erythematosus | 0.93 (0.49–1.79)f | 0.84 | 0.81 (0.40–1.64)f | 0.56 |
Sjögren’s syndrome | 2.05 (1.39–3.01)f | < 0.01 | 1.29 (0.84–1.99)f | 0.25 |
Rheumatoid arthritis | 0.70 (0.50–0.99)f | 0.04 | 0.46 (0.33–0.65)e | < 0.01 |
Systemic sclerosis | 1.65 (0.45–6.02)e | 0.45 | 1.65 (0.45–6.02)e | 0.45 |
Dermatomyositis | 0.95 (0.22–4.02)f | 0.94 | 0.29 (0.04–1.99)f | 0.21 |
Polymyositis | 7.96 (0.97–65.56)f | 0.05 | 7.96 (0.97–65.56)f | 0.05 |
Thromboangiitis obliterans | 16.62 (2.78–99.52)a | < 0.01 | 16.62 (2.78–99.52)a | < 0.01 |
Behcet’s disease | 20.37 (5.54–74.85)f | < 0.01 | 26.20 (6.27–109.45)e | < 0.01 |
Pemphigus | 0.97 (0.07–13.48)d | 0.98 | 0.97 (0.07–13.48)d | 0.98 |
Sarcoidosis | 5.39 (2.15–13.48)f | < 0.01 | 6.09 (2.38–15.58)f | < 0.01 |
Vitiligo | 1.55 (0.73–3.32)f | 0.26 | 1.42 (0.63–3.22)f | 0.40 |